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ORIGINAL RESEARCH
Objective: The aim of this naturalistic study was to evaluate the impact of the duration of
untreated illness (DUI) on the outcome and treatment response of panic disorder (PD).
Methods: Ninety-six outpatients with PD who underwent an 8-week open-label treatment
with serotonergic antidepressants were subdivided into two subgroups: those with DUI ≤ 1
year and those with DUI > 1 year. The main baseline demographic and clinical variables were
calculated and compared between the two subgroups of patients (chi-square test or t-test for
independent samples). The effect of the antipanic medication was evaluated by analysis of
variance with repeated measures considering Hamilton Rating Scale for Anxiety, Clinical
Global Impression rating scores, and the number of panic attacks/week as the dependent
variables (outcome measures), while the subgroups were the independent ones. Comorbidity
with onset later than PD was also considered.
Results: There were no differences between patients with DUI ≤ 1 year and patients with
DUI > 1 year with respect to the outcome measures considered. However, patients with DUI > 1
year (N = 64) had a higher frequency of comorbid major depressive disorder (MDD) with
onset later than PD (p = 0.006).
Conclusions: Results from this study suggest that the DUI may be a predictor of the
development of comorbid MDD in PD. Further investigations on larger samples and with
longer follow-up are warranted.
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Introduction
Panic disorder (PD) is considered a chronic and debilitating illness characterized by
recurrent, severe, and spontaneous anxiety attacks accompanied by a wide variety of
autonomic symptoms (Dannon et al 2004). Some population-based epidemiological
studies showed that approximately 15% of subjects experience isolated panic attacks and
up to 3.8% develop full-syndromal PD during the course of their life (Eaton et al 1994).
PD is often comorbid with other psychiatric disorders such as bipolar disorder,
major depressive disorder (MDD), and other anxiety disorders (Diler et al 2004;
Westenberg et al 2004). In addition, PD is associated with a significant impact on
global functioning and quality of life (Starcevic et al 1993; Carpiniello et al 2002).
The functional disability and risk of suicidal ideation and behavior associated with
comorbid panic and depression far exceed those associated with either disorder alone
(Markowitz et al 1989; Goodwin et al 2001). Recently, Bittner et al (2004) suggested
that anxiety disorders (including panic disorder) act as risk factors for the first onset
of MDD. Furthermore, the presence of several clinical characteristics of anxiety
disorders (eg, specific phobia, social phobia, panic disorder, agoraphobia, and
generalized anxiety disorder), and the presence of more than one anxiety disorder
with severe impairment of global functioning appear to play a substantial role in
determining the susceptibility to MDD.
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Although several effective pharmacological treatments
do exist for PD, up to 20%–40% of patients can be
considered nonresponders to pharmacotherapy, thus
accounting for most of the individual and society costs
associated with the illness (Slaap and den Boer 2001). Some
clinical variables have been most consistently identified as
predictors of poor outcome in PD: panic severity, presence
of agoraphobia, comorbid depression, comorbid personality
disorder, duration of illness, and female gender (Pollack et
al 2000).
Duration of untreated illness (DUI), defined as the time
elapsing from the onset of an illness and the first adequate
treatment, has been considered an important predictive
variable for the course of some psychiatric disorders such
as schizophrenia (Altamura et al 2001). However, the role
of the DUI in mood disorders is still controversial (Craig et
al 2000; Mundo et al 2002). Only few studies exist on the
possible association between a longer DUI and a poorer
outcome in PD (Scheibe and Albus 1997; Katscing et al
1998; Shinoda et al 1999).
The primary aim of this study was to evaluate the impact
of the DUI on the course and the pharmacological treatment
response in PD.
Methods
This naturalistic study included 96 patients (26 males and
70 females) with PD, with or without agoraphobia,
diagnosed by a semistructured psychiatric interview based
on DSM-IV criteria, and treated with SSRIs, venlafaxine or
clomipramine. Treatment was chosen and administered by
the treating psychiatrists at flexible doses, adjusted
according to clinical needs and tolerability. For the 8-week
study duration no concomitant treatment (pharmacological
or nonpharmacological) was allowed except for previously
stabilized doses of benzodiazepines (not exceeding 5 mg
diazepam eq/day). After a complete description of the study,
written informed consent to participate was obtained from
all subjects.
At baseline, the following clinical variables were
collected: age, age at onset, DSM-IV Axis I diagnoses,
family history (FH) for anxiety or mood disorders in first-
degree relatives, and the duration of untreated illness (DUI)
defined as the interval (months) between the onset of PD
and the first adequate (considering time and doses) antipanic
pharmacological treatment.
Data on the DUI were collected using semistructured
clinical interviews and further confirmed using the clinical
charts available for each patient. Patients were also
subdivided into two subgroups: with DUI ≤ 1 year and with
DUI > 1 year. Clinical assessment was done at baseline and
after 8-weeks of treatment by administration of the Hamilton
Rating Scale for Anxiety (HAM-A) (Guy 1976), the
Clinical Global Impression rating scale (CGI) (severity item)
(Guy 1976), and by evaluation of the number of panic
attacks/week.
The main baseline demographic and clinical variables
were calculated and compared between the two subgroups
of patients (chi-square test or t-test for independent samples).
The treatment efficacy and the difference between the two
patient subgroups were evaluated using analysis of variance
(ANOVAs) with repeated measures. In these analyses the
HAM-A score, CGI score (impairment item), and number
of panic attacks/week were the dependent variables.
Results
The main demographic and baseline clinical variables in
the two subgroups of patients are summarized in Table 1.
Patients with DUI ≤ 1 year and patients with DUI > 1 year
did not differ with respect to baseline clinical characteristics,
including FH for anxiety or mood disorders in first degree
relatives.
The clinical assessment after 8-weeks treatment with
serotonergic antidepressants (venlafaxine, n = 6, mean
100 ± 38.7 mg/day; sertraline n = 34, mean 88.9 ± 26.9 mg/day;
clomipramine n = 9, mean 86.1 ± 13.2 mg/day; paroxetine
n = 43, mean 27.0 ± 8.3 mg/day; citalopram n = 1, 20 mg/day;
fluoxetine n = 3, mean 40 ± 20 mg/day) showed a significant
improvement in the whole sample, with no differences
Table 1 Baseline demographic and clinical characteristics in
the whole sample and in the two subsamples defined by the
duration of untreated illness (DUI)
Total DUI ≤ ≤ ≤ ≤ ≤ 1 year DUI > 1 year
Variables (N = 96) (N = 32) (N = 64)
Gender 26 M, 70 F 12 M, 20 F 14 M, 50 F
Age 40.14 (13.05) 35.6 (12.4) 42.5 (12.8)
Age at onset 32.26 (12.75) 34.00 (11.12) 31.39 (13.49)
Panic attacks/week 3.86 (2.16) 3.44 (1.90) 4.08 (2.26)
Positive FH for
anxiety disorders 34 14 20
Positive FH for
mood disorders 12 5 7
HAM-A baseline 19.90 (3.56) 19.22 (3.65) 20.23 (3.50)
CGI baseline
(severity) 3.76 (0.83) 3.59 (0.91) 3.84 (0.78)
NOTE: SDs for continuous variables are shown in parentheses.
Abbreviations: CGI, Clinical Global Impression Scale; DUI, duration of illness;
FH, family history in first degree relatives; HAM-A, Hamilton Rating Scale for
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between patients with DUI ≤ 1 year and patients with DUI > 1
year on the HAM-A total score (time effect: F = 306.314,
p < 0.00001; group effect: F = 3.127, p = 0.08; time × group
effect: F = 0.334, p > 0.50), on the number of panic attacks/
week (time effect: F = 156.457, p < 0.00001; group effect:
F = 1.525, p > 0.020; time × group effect: F = 0.992, p > 0.30),
and on the CGI improvement item score (time effect:
F = 244.314, p < 0.00001; group effect: F = 3.304, p > 0.07;
time × group effect: F = 0.127, p > 0.70).
Patients with DUI > 1 year had a higher frequency of
comorbid MDD with onset later than PD (chi-square = 7.518,
dF = 1, p = 0.006) than patients with DUI ≤ 1 year. These
results did not change when we categorized patients
according to gender, diagnostic subtype (presence/absence
of agoraphobia), or presence/absence of positive FH for
anxiety or mood disorders in first degree relatives.
Discussion
The results from this study do not appear to confirm that a
longer DUI is a predictor of poorer response to pharmaco-
therapy, as it has been reported in previous studies (Slaap
and den Boer 2001).
On the other hand, in this sample, PD patients with
DUI > 1 year had a course complicated by the occurrence
of comorbid major depression (44%) more often than PD
patients with DUI ≤ 1 year (31%). According to the literature,
MDD is highly comorbid with anxiety disorders, which
commonly have earlier onset and represent a significant risk
factor for the development of depression itself (Hettema et
al 2003; Bittner et al 2004). The association between a delay
in the treatment of PD and the development of depressive
episodes has been suggested by previous studies (Scheibe
et al 1997; Katscing et al 1998; Shinoda et al 1999). The
exact nature of this association and the pathogenetic
mechanism underlying the comorbidity between PD and
MDD are still obscure. The presence of common biological
characteristics between the two clinical conditions (eg,
alterations in the hypothalamic-pituitary-adrenal axis
function, in serotonergic neurotransmission, and in growth
hormone response to challenges) suggests some shared
biological susceptibility (Johnson et al 1995).
In any case, the results from this preliminary naturalistic
study suggest that early PD diagnosis and treatment may
positively affect the risk of developing MDD. In addition,
preventing the development of MDD in PD patients by early
pharmacological treatment may have important clinical
implications. As an example, high rates of suicide attempts
or suicidal behavior have been observed in PD patients with
comorbid depression (Goodwin et al 2001), and early
antipanic treatment may be a critical prevention strategy.
Limitations of this study are represented by the relatively
small sample, the naturalistic design, and the relatively short
follow-up. Future research will consider larger samples,
controlled treatments, and longer follow-up.
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